Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Ferrari NV (RACE) Price & Performance

Heron Therapeutics IncTrade
Ferrari NVTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Ferrari NV — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Ferrari NV trades at $389.77 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 990.3× Heron Therapeutics Inc's market cap, and Ferrari NV pays a 1.09% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Ferrari NV for 126 Days on average.

HRTXRACE
Market Cap
$68.01M$67.35B
Volume
1,891,941390,618
Sector
HealthConsumer Cyclical
52-Week High
$1.49$436.54
52-Week Low
$0.27$314.63
Typical Hold Time
35 Days126 Days
Enterprise Value
$174.75M$69.22B
Dividend Yield
—1.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.

While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.

Ferrari NV

Ferrari (RACE) trades at $390.13, up 0.97% today, with a bearish technical signal but strong fundamentals including 22.25% net income margin and consistent earnings beats. Revenue grew to $7.15B in 2025, and the company is executing a share buyback program. Analyst consensus is bullish with a $462.75 price target, though technical indicators show resistance near $390.

The stock offers upside based on premium brand strength and profitability, but faces risks from high valuation multiples (P/E 37.19) and economic sensitivity. Institutional accumulation and positive media coverage support sentiment, yet investors should weigh technical resistance against fundamental growth prospects.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRTX
8% Buy92% Sell
Avg holding period · 35 Days
RACE
0% Buy100% Sell
Avg holding period · 126 Days

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →

About Ferrari NV

Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.

Read more on RACE →